Watchmaker Genomics, the Boulder, Colorado-based NGS reagents company founded by veterans of Kapa Biosystems and ArcherDX, is taking two new products to the 59th European Human Genetics Conference (ESHG 2026) in Gothenburg, Sweden this week. The announcements — the EquiPlex Normalization Kit and the Equinox Prime Library Amplification Master Mix — target problems that genomics labs have lived with for years: the tedium and variability of library normalization before pooling, and the accuracy trade-offs that creep into amplification-heavy workflows.
Both products debut in a featured workshop on June 15, and both address what has become a defining tension in modern sequencing operations: the sequencers keep getting faster, but the preparation steps haven't kept pace. As throughput scales, those preparation steps increasingly set the ceiling on how many samples a lab can process reliably in a run.
Editor's Note: Library preparation has long been the unglamorous bottleneck in NGS workflows, and that gap has widened as sequencer throughput has outpaced the upstream chemistry designed to feed it. Watchmaker Genomics' dual launch at ESHG 2026 arrives at a moment when genomics labs are under real operational pressure: more samples, tighter budgets, and growing demand for clinical-grade accuracy. Lab managers evaluating either product will want to weigh compatibility with existing automation and the cost of validating new reagents against their current workflows.
Watchmaker Genomics, the Boulder, Colorado-based NGS reagents company founded by veterans of Kapa Biosystems and ArcherDX, is taking two new products to the 59th European Human Genetics Conference (ESHG 2026) in Gothenburg, Sweden this week. The announcements — the EquiPlex Normalization Kit and the Equinox Prime Library Amplification Master Mix — target problems that genomics labs have lived with for years: the tedium and variability of library normalization before pooling, and the accuracy trade-offs that creep into amplification-heavy workflows.
Both products debut in a featured workshop on June 15, and both address what has become a defining tension in modern sequencing operations: the sequencers keep getting faster, but the preparation steps haven't kept pace. As throughput scales, those preparation steps increasingly set the ceiling on how many samples a lab can process reliably in a run.
Why library normalization is still a problem for high-throughput labs
Pooling multiple sequencing libraries into a single run is routine, but achieving equimolar representation across libraries is anything but. Standard normalization requires measuring each library's concentration, performing dilution calculations, and adjusting pipetting volumes accordingly, all steps that are error-prone, difficult to automate cleanly, and often produce enough residual variability that labs still face uneven coverage and data loss downstream.
Automation platforms have improved library preparation throughput considerably, but the normalization step has remained a stubborn exception. Variable-volume pipetting, in particular, is hard to automate reliably, and any inconsistency at this stage compounds directly into sequencing imbalance: samples that were slightly under-represented get under-sequenced, and labs either accept lower coverage or rerun the sequencing at additional cost.
The scale problem has intensified as sequencers have grown more powerful. A January 2026 analysis in Genetic Engineering & Biotechnology News described a "throughput paradox" in the industry: instruments like the Illumina NovaSeq X+ and the PacBio Revio have pushed data generation capacity far ahead of what upstream library preparation can supply without bottlenecks. The constraint has migrated upstream, from the sequencer to the bench.
EquiPlex addresses this by repurposing CRISPR-Cas9 technology as a stoichiometric molecular capture tool rather than a cutting enzyme. The system uses adapter-specific guide RNAs to bind a fixed, predetermined number of molecules from each library, independent of its starting concentration. Because the capture is stoichiometric rather than concentration-dependent, labs can skip quantification QC, dilution calculations, and variable-volume pipetting entirely. The kit is designed to integrate with existing RNA-seq, DNA-seq, and methylation workflows without requiring labs to overhaul their established protocols.
Interested in life sciences?
The intellectual property underpinning this approach has been in development for some time. In February 2026, Watchmaker licensed foundational CRISPR-Cas9 IP from Caribou Biosciences specifically for this application, alongside a recently issued patent for the approach. The EquiPlex kit is the commercial product that delivers on that licensing strategy.
Early validation data from a real-world genomics core provides some useful signal. Graham Wiley, PhD, Staff Scientist and Director of the Clinical Genomics Center at Oklahoma Medical Research Foundation, noted that conventional pipelines had consistently left residual variability that required additional sequencing to reach coverage goals. "With EquiPlex we've finally found the level of pooling consistency we were searching for," Wiley said.
Watchmaker is also extending the same CRISPR-Cas9 normalization approach as a core component of a PCR-free whole genome sequencing solution, designed for labs that need reproducible WGS data at scale for applications including population genomics, newborn screening, and rare disease research.
Equinox Prime: addressing amplification accuracy in demanding oncology workflows
The second launch, Equinox Prime Library Amplification Master Mix, is aimed at a different but related problem: amplification errors in genomic regions prone to polymerase slippage.
Repetitive genomic sequences and homopolymers present a well-documented challenge for NGS amplification. Polymerases can slip during replication of these regions, generating insertion and deletion artifacts (indels) that are difficult to distinguish from genuine variants. In most applications, these artifacts are a nuisance. In oncology workflows, they can be clinically significant.
Microsatellite instability (MSI) profiling is the most acute example. MSI is a marker of mismatch repair deficiency, a predictive indicator for immune checkpoint inhibitor therapy response, and is routinely evaluated across a growing range of tumor types beyond colorectal cancer. NGS-based MSI detection depends directly on the accuracy of indel calls at homopolymer and microsatellite loci, which is precisely where polymerase slippage introduces the most noise. Amplification artifacts in these regions can inflate mutation burden estimates, distort MSI classification, and affect treatment eligibility assessments.
Watchmaker engineered Equinox Prime specifically to reduce polymerase slippage in these regions. The product also delivers low error rates, high library yields, and uniform GC coverage, addressing a set of trade-offs that labs have historically been forced to accept in amplification chemistry.
Brian Kudlow, Co-Founder and CSO of Watchmaker, framed the engineering challenge plainly: "Researchers have historically had to make trade-offs in library amplification performance, balancing yield and coverage uniformity against sequencing accuracy depending on the application. Equinox Prime was engineered to eliminate those compromises by delivering improved indel accuracy in repetitive regions alongside low error rates, high yields, and even GC coverage in a single solution."
Beyond MSI profiling, the product is positioned for whole genome sequencing, whole exome sequencing, and other applications where amplification performance directly affects downstream data quality. The link between amplification quality and downstream sequencing accuracy is well established, and the case for a single reagent that no longer forces labs to choose between yield and fidelity is straightforward.
Key features at a glance
EquiPlex Normalization Kit:
- Uses Cas9 as a stoichiometric binding tool (not a cutting enzyme) to capture a fixed number of library molecules per sample
- Eliminates library concentration QC, dilution calculations, and variable-volume pipetting steps before pooling
- Compatible with RNA-seq, DNA-seq, and methylation sequencing workflows
- Designed for automation-compatible, high-throughput operations
- Foundational to Watchmaker's forthcoming PCR-free WGS solution
Equinox Prime Library Amplification Master Mix:
- Engineered to reduce polymerase slippage in homopolymer and repetitive genomic regions
- Improves indel accuracy for MSI profiling and somatic oncology sequencing applications
- Delivers low error rates, high library yields, and uniform GC coverage in a single formulation
- Applicable across WGS, WES, and other sequencing workflows
How EquiPlex and Equinox Prime compare to conventional approaches
| Feature | Conventional normalization + amplification | EquiPlex + Equinox Prime |
|---|---|---|
| Normalization method | qPCR quantification, dilution calculations, variable-volume pipetting | Stoichiometric Cas9 capture; concentration-independent |
| Pre-pooling QC required | Yes | Eliminated |
| Automation compatibility | Limited by variable-volume pipetting | Designed for automation |
| Indel accuracy in repetitive regions | Subject to polymerase slippage artifacts | Engineered to reduce slippage |
| Workflow disruption | Drop-in to existing protocols | Compatible with existing library prep workflows |
| MSI profiling suitability | Variable; artifacts possible | Improved indel accuracy supports MSI applications |
What Watchmaker's trajectory tells us
Watchmaker Genomics was founded in 2019 by Trey Foskett, Brian Kudlow, and Stephen Picone — three scientists whose combined background includes senior roles at Kapa Biosystems, ArcherDX, and Roche. A $40 million Series A in 2022, led by Decheng Capital, brought total funding to $53.5 million and was positioned around expanding into clinical sequencing, single-cell analysis, and epigenetics.
The EquiPlex and Equinox Prime launches are consistent with that strategy. The company has moved steadily from foundational enzyme engineering toward clinical-facing reagents, with its TAPS epigenetics technology (co-exclusively licensed from the University of Cambridge in partnership with Exact Sciences) and now these two products that directly address workflow pain points in high-throughput and oncology-focused sequencing settings.
Foskett positioned the launches in operational terms: "Sequencing workflows continue to grow in scale and complexity, but many of the core bottlenecks researchers face today remain fundamentally unchanged. These launches reflect our focus on engineering technologies that not only improve data quality but also simplify workflows and enable researchers to operate more efficiently at scale."
What these launches mean for your NGS operation
For lab managers running high-throughput sequencing operations, EquiPlex's promise is mainly about reducing a labor-intensive and error-prone step that consumes skilled staff time and still produces variability. If validation bears out the normalization consistency that early users report, the operational case for adoption is clear: fewer concentration measurements, more predictable pooling, and less waste from imbalanced runs.
Equinox Prime is more application-specific but addresses a genuine gap in oncology sequencing. Labs performing MSI profiling or somatic variant calling in repetitive regions have limited options for improving indel accuracy without sacrificing yield or coverage uniformity. A single reagent that delivers on all three criteria simultaneously is worth evaluating carefully against current in-house performance benchmarks.
Both products will be showcased at Watchmaker's featured workshop at ESHG 2026, "From Multiomics to Multiplexing: Integrated Advances in DNA, RNA, and Epigenomic Profiling," on June 15 in Gothenburg.
References
- Watchmaker Genomics. "Watchmaker to Unveil New Technologies Addressing NGS Workflow Bottlenecks and Sequencing Accuracy Challenges at ESHG 2026." BusinessWire, June 10, 2026. https://www.biospace.com/press-releases/watchmaker-to-unveil-new-technologies-addressing-ngs-workflow-bottlenecks-and-sequencing-accuracy-challenges-at-eshg-2026
- Watchmaker Genomics. "Watchmaker Genomics Licenses CRISPR-Cas9 Technology from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample." February 17, 2026. https://www.watchmakergenomics.com/news/caribou_021726
- Verma, P.K. et al. "Maximizing the potential of high-throughput next-generation sequencing through precise normalization based on read count distribution." mSystems, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469589/
